David Swoboda

Has grant

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Evaluation of Clonal Hematopoiesis of Indeterminate Potential as a Predictor of Adverse Events in CAR-T patients

Open Date: 2020-09-01

Close Date: 2021-06-01

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Nathan Montgomery

Assistant Professor

University of North Carolina

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Swoboda

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax

A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with NPM1 and IDH2 mutations

Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations

Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts

Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.

Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

PTPN11 mutations are associated with poor outcomes across myeloid malignancies.

The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.

Novel therapies in myelodysplastic syndromes.

Collaborators (1)

Nathan Montgomery

Make your next move.